Aslan Pharmaceuticals Pte. Ltd., of Singapore, and National Cancer Centre Singapore (NCCS) have agree to initiate a number of collaborative projects focused on increasing the understanding of novel combinations of known therapeutic agents, including Aslan's clinical development programs ASLAN001 and ASLAN002, through preclinical research involving patient-derived cell lines and xenograft models.